References
Saneto RP. Mitochondrial diseases: expanding the diagnosis in the era of genetic testing. J Transl Genet Genom. 2020;4:384–428.
Emmanuele V, Ganesh J, Vladutiu G, Haas R, Kerr D, Saneto RP, et al. Time to harmonize mitochondrial syndrome nomenclature and classification: a consensus from the North American Mitochondrial Disease Consortium, (NAMDC). Mol Genet and Metab. 2022;136:125–31.
Russell OM, Gorman GS, Lightolers RN, Turnbull DM. Mitochondrial diseases: hope for the future. Cell. 2020;181:168–88.
Karaa A, Klopstock T. Clinical trials in mitochondrial diseases. Handb Clin Neurol. 2023;194:229–50.
DiVito D, Wellik A, Burfield J, Peterson, J, Flickinger J, Tindall A, et al. Clinical nutrition in mitochondrial disease correlates to improved muscle fatigue, strength, and quality of life. Neurotherapeutics. 2023 (this issue).
Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;2(17):491–506.
Sturm G, Karan KR, Monzel AS, Santhanam B, Taivassalo T, Bris C, et al. OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases. Commun Biol. 2023;6:22.
Kyriazis ID, Vassi E, Alvanou M, Angelakis C, Skaperda Z, Tekos F, et al. The impact of diet upon mitochondrial physiology (Review). Int J Mol Med. 2022;50:135.
Karaa A, Kriger J, Grier J, Holbert A, Thompson JL, Parikh S, et al. Mitochondrial disease patients’ perception of dietary supplements’ use. Mol Genet Metab. 2016;119:100–8.
Zolkipli-Cunningham Z, Xiaxo R, Stoddan A, McCormick EM, Holberts A, Burrill N, et al. Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS ONE. 2018;13:e0197513.
Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, et al. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial. Neurology. 2020;18(94):e687–98.
Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909–18.
Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212–21. Erratum in: Neurology. 2018;90:669. Erratum in: Neurology. 2018 Nov 20; 91:986.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Saneto, R.P., Karaa, A. Optimized Nutrition in Mitochondrial Diseases Correlates with Improved Muscle Fatigue, Strength, and Quality of Life: You Are What You Eat, or Are You?. Neurotherapeutics 20, 1694–1695 (2023). https://doi.org/10.1007/s13311-023-01445-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13311-023-01445-6